TBPH Q1 2019 Earnings — Theravance Biopharma, Inc. Revenue & Financial Results | Market Cap Arena

TBPHTheravance Biopharma, Inc.

$697M

Q1 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$5M-35.8% YoY

Gross Profit

-$48M-908.2% margin

Operating Income

-$74M-1380.0% margin

Net Income

-$73M-1359.7% margin

EPS (Diluted)

$-1.32

QoQ Revenue Growth

-66.1%

Cash Flow

Operating Cash Flow

-$81M

Free Cash Flow

-$82M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$531M

Total Liabilities

$645M

Stockholders' Equity

-$113M

Cash & Equivalents

$223M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$5M	$8M	-35.8%
Gross Profit	-$48M	$7M	-747.0%
Operating Income	-$74M	-$65M	-13.4%
Net Income	-$73M	-$65M	-11.5%

Revenue Segments

Collaborative Arrangement Revenue

$5M100%